[HTML][HTML] Mortality in SARS-CoV-2 hospitalized patients treated with Remdesivir: a nationwide, registry-based study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - Viruses, 2022 - mdpi.com
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy.
P Russo, E Tacconelli, PP Olimpieri… - Viruses (1999 …, 2022 - search.ebscohost.com
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - …, 2022 - search.proquest.com
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy.
P Russo, E Tacconelli, PP Olimpieri, S Celant… - Viruses, 2022 - europepmc.org
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
R Pierluigi, E Tacconelli, OP Paolo, C Simone… - VIRUSES, 2022 - iris.univr.it
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - 2022 - agris.fao.org
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
[HTML][HTML] Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - Viruses, 2022 - ncbi.nlm.nih.gov
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy.
P Russo, E Tacconelli, PP Olimpieri, S Celant… - Viruses, 2022 - europepmc.org
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …